Abstract: Novel antifungal antibiotic compounds have the structural formula ##STR1## A preferred compound where R is 4-hydroxypentyl is denoted BU-3557B.sub.2. A complex of said compounds is produced by fermenting a culture of Sacchrothrix aerocolonigenes strain N806-4 (ATCC 53712). The complex is recovered by adsorption on nonionic porous polymer resin adsorbent and individual component compounds exhibit in vitro activity against fungi and Gram-positive bacteria and BU-3557B.sub.2 demonstrates in vitro antiprotazoal activity. BU-3557B.sub.2 demonstrates in vivo activity against C. albicans vaginal infection and BU-3557A.sub.3 (where R is 1,5-dihydroxy-5,5-dimethylpentyl) demonstrates in vivo activity against C. albicans systemic infection.
Abstract: There are disclosed new naphthyridine- and quinoline-carboxylic acids having a 1-tertiary-alkyl substituent, compositions containing them, and their use in treating bacterial infections in warm-blooded animals. Also disclosed are novel amines and intermediates used in the preparation of the naphthyridine- and quinoline-carboxylic acids.
Type:
Grant
Filed:
December 19, 1988
Date of Patent:
September 4, 1990
Assignee:
Bristol-Myers Company
Inventors:
Abraham Weber, Daniel Bouzard, Munir Essiz, Pierre Di Cesare, Jean-Pierre Jacquet, Philippe Remuzon
Abstract: A process for the selective formation of oximino o-protected derivatives of lower alkyl 2-(2-aminothiazol-4-yl)-2-oximinoacetates, and their use in the acylation of 7-amino-cephalosporin compounds is disclosed.
Abstract: Etoposide-3',4'-quinone is converted into a phosphorane or phosphate ester by reaction with an organic phosphine or phosphite. The resulting phosphoranes and phosphates have anti-tumor activity in animals.
Abstract: Crystalline sulfuric, di-nitric, mono-hydrochloric, di-hydrochloric, and di- and sesqui-orthosphosphoric acid addition salts of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(Z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate are stable even at elevated temperatures. The crystalline sulfuric acid addition salt is made by forming an admixture of (a) at least one molar equivalent of sulfuric acid with (b) zwitterion in an amount so as to be present in the admixture at a concentration of greater than 25 milligrams/ml, causing crystallization, separating the crystals, washing and drying. The crystalline monohydrochloride, dihydrochloride, and orthophosphate salts are prepared by dissolving the zwitterion in the appropriate amount of acid, causing crystallization by adding acetone and isolating the crystals. Physical admixtures of the salts with certain bases in proportions to give a pH ranging from about 3.
Type:
Grant
Filed:
January 19, 1988
Date of Patent:
March 20, 1990
Assignee:
Bristol-Myers Company
Inventors:
Murray A. Kaplan, Thomas W. Hudyma, Robert A. Lipper, Kun M. Shih, Susan D. Boettger
Abstract: There are disclosed novel 2',3'-dideoxy-2'-fluoronucleosides and 2'-3'-dideoxy-2',3'-didehydro-2'-fluoronucleosides and processes for their preparation. The compounds so produced exhibit therapeutically useful antiviral and, more particularly, anti-HIV effects.
Type:
Grant
Filed:
November 12, 1987
Date of Patent:
March 13, 1990
Assignee:
Bristol Myers Company
Inventors:
Roman Z. Sterzycki, Muzammil M. Mansuri, John C. Martin
Abstract: There are disclosed novel processes for producing 2',3'-dideoxy-2'3'-didehydronucleosides, for example, 2',3'-dideoxy-2',3'-didehydrothymidine in high yields and on a large scale. The compounds so-produced are useful as antiviral agents, especially as agents effective against the human immunodeficiency viruses (HIV).
Type:
Grant
Filed:
March 24, 1988
Date of Patent:
February 27, 1990
Assignee:
Bristol-Myers Company
Inventors:
John E. Starrett, Jr., Muzammil M. Mansuri, John C. Martin, Carl E. Fuller, Henry G. Howell
Abstract: Process for producing 1-halo-2-deoxy-2-fluoroarabinofuranoside derivatives bearing protective ester groups from 1,3,5-tri-O-acylribofuranose; the 1-halo compounds are intermediates in the synthesis of therapeutically active nucleosidic compounds.
Type:
Grant
Filed:
July 28, 1988
Date of Patent:
November 7, 1989
Assignee:
Bristol-Myers Company
Inventors:
Steven P. Brundidge, Henry G. Howell, Chester Sapino, Jr., Chou Hong-Tann
Abstract: This invention provides novel cephalosporanic acids and esters thereof having the general formula ##STR1## wherein R.sup.2 is hydrogen, or lower acyl, R.sup.3 is hydrogen, or lower alkanoyloxy, andR.sup.4 is hydrogen, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl, 1-(ethoxycarbonyloxy)ethyl,1-(pivaloyloxy)ethyl, 1-(cyclohexylacetoxy)ethyl, or 1-(cyclohexyloxycarbonyloxy) ethyl. These compounds, especially esters, are useful as broad spectrum antibiotics in the treatment and prevention of infectious diseases of mammals, and for other purposes known in the art. The acids (R.sup.4 is hydrogen) are useful as intermediates for making the esters.
Abstract: There is disclosed a process for the production of certain 3-hydrocarbyl-3-cephem derivatives wherein the hydrocarbyl group is selected from 1-alkenyl and conjugated and unconjugated 1-polyalkenyl, 1-alkynl, carbocyclic and heterocyclic aryl, and carbocyclic and heterocyclic arylmethyl and, in the case of the 1-alkenyl and conjugated 1-polyalkenyl derivatives, with substantially complete stereospecificity, by coupling a 3-triflyloxy cephem with a hydrocarbyltributylstannane in the presence of bis(dibenzylideneacetonyl)-palladium, a phosphine, and a metal halide such as, for example, zinc chloride. The 3-unsaturated alkyl-3-cephem derivatives so-produced are useful as broad-spectrum antibacterial agents.
Type:
Grant
Filed:
February 26, 1987
Date of Patent:
September 26, 1989
Assignee:
Bristol-Myers Company
Inventors:
Stephen R. Baker, Vittorio Farina, Chester Sapino, Jr.
Abstract: This invention refers to 7-amino mitosane analogs (mitomycin C) in which the 7-amino group bears an organic substituent incorporating a disulfide group and to a novel thiol exchange process for producing these compounds. The compounds are inhibitors of experimental animal tumors.
Type:
Grant
Filed:
September 23, 1985
Date of Patent:
September 12, 1989
Assignee:
Bristol-Myers Company
Inventors:
Dolatrai M. Vyas, Yulin Chiang, Terrence W. Doyle
Abstract: There is disclosed a process for the production of certain 2-allyl- and 3-butenyl-3-cephem derivatives by coupling a 3-chloromethyl-3-cephem with a hydrocarbyltributystannane in the presence of bis(dibenzylideneacetonyl)-palladium and a phosphine. The 3-allyl- and 3-butenyl-3-cephem derivatives so-produced are useful as broad-spectrum antibacterial agents.
Type:
Grant
Filed:
February 26, 1987
Date of Patent:
July 11, 1989
Assignee:
Bristol-Myers Company
Inventors:
Stephen R. Baker, Vittorio Farina, Chester Sapino, Jr.
Abstract: There is disclosed a process for producing carbapenam diazo intermediates of the formula ##STR1## wherein R.sup.1 is hydrogen or a hydroxy-protecting group,R.sup.2 is a lower alkyl having from 1-6 carbon atoms, andR.sup.3 represents a conventional carboxyl-protecting group.The processs comprises alkylating a 4-substituted azetidinone with the tin enolate of an .alpha.-bromoketone, in the presence of a silver salt, iodine, or iodine salt as a catalyst, and a strongly polar solvent. The .beta./.alpha. yield of the product diazo intermediate is approximately 3/1.
Abstract: The present invention refers to mitomycin analogs containing a disulfide group. These compounds are mitromycin C derivatives in which the 7-amino group bears an organic substituent incorporating a disulfide group. The compounds are inhibitors of experimental animal tumors.
Type:
Grant
Filed:
February 24, 1984
Date of Patent:
February 7, 1989
Assignee:
Bristol-Myers Company
Inventors:
Dolatrai M. Vyas, Yulin Chiang, Terrence W. Doyle
Abstract: A process is disclosed for the deprotection of allylic esters and ethers. The process comprises reacting an allyl ester of a carboxylic acid or an allyl ether of a phenol with pyrrolidine or piperidine and a catalytic amount of an organic-soluble palladium complex having a coordinating phosphine ligand to cleave the allyl moiety. The resultant carboxylic acid or phenol is then recovered.
Abstract: The actinomycete "Actinomadura sp." designated in our culture collection as Strain No. G455-101 has been deposited with the American Type Culture Collection under the Accession Number ATCC No. 31491. The taxonomic description of this microorganism is presented in detail in the specification as are instructions for fermenting aqueous nutrient media with it to produce the BBM 928 antibiotic complex. The BBM 928 complex has utility as an antibacterial agent against gram-positive and acid fast bacteria and exhibits antitumor activity against experimental animal tumors.
Abstract: The antibiotic 7-[D-2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-1-propenyl]ceph-3-em-4-c arboxylic acid (BMY-28100) forms imidazolidinone derivatives on reaction with ketones. These derivatives are useful in pharmaceutical dosage forms and as intermediates for separation thereof from mixtures containing the [(E)-1-propenyl]isomer of the antibiotic.
Type:
Grant
Filed:
November 25, 1985
Date of Patent:
February 23, 1988
Assignee:
Bristol-Myers Company
Inventors:
Murray A. Kaplan, Michael W. Lovell, Joseph B. Bogardus
Abstract: This invention provides novel cephalosporanic acids and esters thereof having the general formula ##STR1## wherein R.sup.2 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl or acyl, R.sup.3 is hydrogen, lower alkyl, lower alkoxy, lower alkanoyloxy, andR.sup.4 is hydrogen, pivaloyloxymethyl, acetoxymethyl, 1-acetoxyethyl, 5-methyl-2-oxo-1, 3-dioxolen-4-ylmethyl or 4-glycyloxybenzoyloxymethyl. These compounds, especially esters, are useful as broad spectrum antibiotics in the treatment and prevention of infectious diseases of mammals, and for other purposes known in the art.
Abstract: 7-[(D)-2-Amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-1-propenyl]ceph-3-em-4- carboxylic acid in the form of its crystalline dimethylformamide solvate (1/1.5) has been provided.
Abstract: The present invention refers to mitomycin analogs containing a disulfide group. These compounds are mitomycin C derivatives in which the 7-amino group bears an organic substituent incorporating a disulfide group. The compounds are inhibitors of experimental animal tumors.
Type:
Grant
Filed:
August 7, 1986
Date of Patent:
September 1, 1987
Assignee:
Bristol-Myers Company
Inventors:
Dolatrai M. Vyas, Yulin Chiang, Terrence W. Doyle